With recent successes of immunotherapies and targeted drugs, melanoma has become one of the most dynamic areas of anticancer drug development.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. Dual fronts poised to transform melanoma therapy. Nat Rev Drug Discov 10, 325–326 (2011). https://doi.org/10.1038/nrd3441
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3441